Uppsala 10th October 2018

Positive results in the feasibility study lead to broader cooperation


AstraZeneca has conducted a feasibility study for investigating specific properties of Nanexa’s drug delivery platform PharmaShell®. The study results have been so positive that AstraZeneca has chosen to broaden its cooperation with Nanexa. Additional interesting substances will be evaluated in combination with PharmaShell®. The companies aim to generate results within this new broader collaboration, which will form the basis for discussions on more specific product projects with PharmaShell®.


Nanexa’s CEO David Westberg comments:

As I previously informed in quarterly reports, the cooperation with AstraZeneca has entered a very interesting phase. AstraZeneca has now carried out a first animal study, which is a very important milestone for Nanexa, and most importantly, has led AstraZeneca to expand its cooperation with us. It is obviously very pleasing and I believe that this continuation can be very rewarding.


For further information:
Nanexa AB (publ)
David Westberg, VD
Phone: +46 709 42 83 03
E mail:


This information is the information Nanexa AB is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on October 11, 2018.

About Nanexa AB (publ)
Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.